Drug Interaction Report

Consumer information for this interaction is not currently available.

CONTRAINDICATED: Coadministration with inhibitors of CYP450 1A2 may significantly increase the plasma concentrations of fezolinetant, which is primarily metabolized by the isoenzyme. In clinical drug interaction studies, coadministration of the potent CYP450 1A2 inhibitor fluvoxamine increased the peak plasma concentration (Cmax) and systemic exposure (AUC) by 80% and 840%, respectively. Likewise, the moderate CYP450 1A2 inhibitor, mexiletine, is predicted through physiologically based pharmacokinetic (PBPK) modeling to increase the Cmax and AUC of fezolinetant by 40% and 360%, respectively. The weak CYP450 1A2 inhibitor cimetidine is also predicted via PBPK to increase the Cmax and AUC of fezolinetant by 30% and 100%, respectively.

MANAGEMENT: Concomitant use of fezolinetant with CYP450 1A2 inhibitors is considered contraindicated.

Consuming food or beverages that contain caffeine (e.G., chocolate, coffee, cola drinks, energy drinks, tea) is not recommended while taking fezolinetant. Caffeine may significantly increase the levels of fezolinetant in the blood. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Information for this minor interaction is available on the professional version.